Compare Abeona Therapeutics Inc (ABEO) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Under Armour Inc Class A — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Under Armour Inc Class A trades at $6.47 (market cap $2.87B). The key difference: Under Armour Inc Class A is far larger — about 7.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| ABEO | UAA | |
|---|---|---|
Market Cap | $373.32M | $2.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $8.14 |
52-Week Low | $4.17 | $4.17 |
Enterprise Value | $228.22M | $4.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Under Armour (UAA) trades at $6.74, up 1.66% today, with a bullish technical signal from moving averages but bearish oscillators. Recent earnings show mixed results, with Q4 2026 beating expectations but Q1 2026 missing. The company faces declining revenue and negative net income margins, though international growth and a new Dodge collaboration offer potential catalysts. Cash flow remains negative, and the balance sheet shows rising debt-to-asset ratios, indicating financial strain.
The outlook is cautious due to weak North American sales and margin pressure, but analyst consensus leans hold with a $5.96 price target. Risks include consumer spending softness and execution challenges, while opportunities lie in international expansion and strategic partnerships. Investors should weigh deteriorating fundamentals against potential turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
